The neuroprotective effects of activated α7 nicotinic acetylcholine receptor against mutant copper-zinc superoxide dismutase 1-mediated toxicity.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 12 2020
Historique:
received: 29 07 2020
accepted: 02 12 2020
entrez: 18 12 2020
pubmed: 19 12 2020
medline: 11 5 2021
Statut: epublish

Résumé

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the selective and progressive loss of motor neurons. Although many drugs have entered clinical trials, few have shown effectiveness in the treatment of ALS. Other studies have shown that the stimulation of α7 nicotinic acetylcholine receptor (nAChR) can have neuroprotective effects in some models of neurodegenerative disease, as well as prevent glutamate-induced motor neuronal death. However, the effect of α7 nAChR agonists on ALS-associated mutant copper-zinc superoxide dismutase 1 (SOD1) aggregates in motor neurons remains unclear. In the present study, we examined whether α7 nAChR activation had a neuroprotective effect against SOD1

Identifiants

pubmed: 33335227
doi: 10.1038/s41598-020-79189-y
pii: 10.1038/s41598-020-79189-y
pmc: PMC7746719
doi:

Substances chimiques

Basic Helix-Loop-Helix Leucine Zipper Transcription Factors 0
Neuroprotective Agents 0
Protein Aggregates 0
TFEB protein, human 0
alpha7 Nicotinic Acetylcholine Receptor 0
Superoxide Dismutase-1 EC 1.15.1.1
TOR Serine-Threonine Kinases EC 2.7.11.1
AMP-Activated Protein Kinases EC 2.7.11.31
Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

22157

Références

FASEB J. 2019 Nov;33(11):12374-12391
pubmed: 31404503
Biol Pharm Bull. 2009 Mar;32(3):332-6
pubmed: 19252273
Nature. 1993 Mar 4;362(6415):59-62
pubmed: 8446170
Sci Rep. 2017 Jun 6;7(1):2882
pubmed: 28588226
J Mol Biol. 2020 Apr 3;432(8):2799-2821
pubmed: 31887286
Brain Res. 2012 Jun 6;1458:67-75
pubmed: 22552114
EMBO J. 2000 Nov 1;19(21):5720-8
pubmed: 11060023
Neuroscience. 2014 Dec 12;282:86-100
pubmed: 24881574
PLoS One. 2010 Jul 14;5(7):e11552
pubmed: 20644736
Curr Opin Neurobiol. 2011 Dec;21(6):904-19
pubmed: 21813273
Nat Rev Drug Discov. 2009 Sep;8(9):733-50
pubmed: 19721446
Stem Cell Res Ther. 2018 Apr 10;9(1):98
pubmed: 29631619
FEBS Lett. 2016 Mar;590(5):672-82
pubmed: 26848942
CNS Neurosci Ther. 2017 Nov;23(11):875-884
pubmed: 28941191
Ann Neurol. 1998 Nov;44(5):796-807
pubmed: 9818936
Exp Neurol. 2018 Nov;309:193-204
pubmed: 30134145
Front Immunol. 2019 Nov 14;10:2650
pubmed: 31798583
Mol Neurodegener. 2019 Mar 27;14(1):14
pubmed: 30917850
J Comp Neurol. 2003 Oct 13;465(2):195-204
pubmed: 12949781
Neurosci Res. 2008 Dec;62(4):254-61
pubmed: 18845194
Nat Neurosci. 2010 Nov;13(11):1396-403
pubmed: 20953194
Mol Cell Neurosci. 2018 Oct;92:177-184
pubmed: 30193933
Neuroscience. 2017 Jan 26;341:112-153
pubmed: 27889578
Genes Dev. 2009 Oct 1;23(19):2294-306
pubmed: 19762508
Sci Transl Med. 2017 May 24;9(391):
pubmed: 28539470
Lancet. 1993 Jan 30;341(8840):265-8
pubmed: 8093916
Cancer Lett. 2016 Mar 28;372(2):226-38
pubmed: 26803057
Nat Med. 2018 Oct;24(10):1579-1589
pubmed: 30127392
Ann Neurol. 1995 Jul;38(1):73-84
pubmed: 7611729
Mol Pain. 2007 Sep 25;3:26
pubmed: 17894865
Front Neurol. 2019 May 21;10:527
pubmed: 31164862
Brain Res. 2004 Jul 23;1015(1-2):73-81
pubmed: 15223368
Biochem Biophys Res Commun. 2005 May 20;330(4):1285-9
pubmed: 15823582
J Neurosci Res. 2018 Jul;96(7):1208-1222
pubmed: 29577375
Neuron. 2010 Dec 9;68(5):857-64
pubmed: 21145000
Cell Death Dis. 2014 Oct 30;5:e1497
pubmed: 25356866
Autophagy. 2014 Apr;10(4):588-602
pubmed: 24441414
Autophagy. 2013 Sep;9(9):1308-20
pubmed: 23851366
Br J Pharmacol. 1996 Aug;118(7):1772-8
pubmed: 8842443
Science. 2009 Feb 27;323(5918):1205-8
pubmed: 19251627
Sci Rep. 2017 Sep 6;7(1):10652
pubmed: 28878377
Cell. 2001 Feb 23;104(4):581-91
pubmed: 11239414
Int J Mol Sci. 2019 Jun 16;20(12):
pubmed: 31208129
Front Immunol. 2017 May 16;8:553
pubmed: 28559895
Aging Dis. 2019 Dec 1;10(6):1159-1173
pubmed: 31788329
Rinsho Shinkeigaku. 2014;54(12):1128-31
pubmed: 25672727
Science. 2015 Mar 27;347(6229):1436-41
pubmed: 25700176
CNS Neurosci Ther. 2018 Dec;24(12):1163-1174
pubmed: 29656576
Cell Death Dis. 2019 Sep 15;10(7):483
pubmed: 31522191
Mol Neurobiol. 2014 Feb;49(1):66-77
pubmed: 23807728
J Clin Invest. 2015 Jun;125(6):2548
pubmed: 26030230
Acta Neuropathol. 2013 Jun;125(6):777-94
pubmed: 23673820
Front Mol Neurosci. 2017 Aug 22;10:263
pubmed: 28878620
Arch Neurol. 2011 Nov;68(11):1440-6
pubmed: 22084127
Trends Pharmacol Sci. 2020 Feb;41(2):99-109
pubmed: 31926602
J Biol Chem. 2007 Aug 17;282(33):24131-45
pubmed: 17580304
J Physiol. 2001 Oct 1;536(Pt 1):101-10
pubmed: 11579160
N Engl J Med. 1994 Mar 3;330(9):585-91
pubmed: 8302340
Autophagy. 2009 May;5(4):502-10
pubmed: 19270530
Eur J Neurosci. 2018 Jun;47(11):1353-1374
pubmed: 29770521
J Neurochem. 2008 Feb;104(4):993-1005
pubmed: 18233996
Trends Pharmacol Sci. 2006 Sep;27(9):482-91
pubmed: 16876883
J Neuroinflammation. 2017 Sep 26;14(1):192
pubmed: 28950908
Nat Commun. 2019 Dec 10;10(1):5630
pubmed: 31822666
Nat Neurosci. 2010 Jul;13(7):805-11
pubmed: 20581817
Lancet. 1996 May 25;347(9013):1425-31
pubmed: 8676624
J Neurosci Res. 2009 Feb;87(2):576-85
pubmed: 18803299
Nature. 2016 Nov 10;539(7628):197-206
pubmed: 27830784
Mol Neurodegener. 2019 Nov 19;14(1):42
pubmed: 31744522
Nature. 2010 May 13;465(7295):223-6
pubmed: 20428114
J Neuropathol Exp Neurol. 1998 Apr;57(4):329-33
pubmed: 9600225
Hum Mutat. 2012 Sep;33(9):1345-51
pubmed: 22753137
Science. 2006 Oct 6;314(5796):130-3
pubmed: 17023659

Auteurs

Taisei Ito (T)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, 1-1-1, Gifu, 501-1196, Japan.

Masatoshi Inden (M)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, 1-1-1, Gifu, 501-1196, Japan.

Tomoyuki Ueda (T)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, 1-1-1, Gifu, 501-1196, Japan.

Yuta Asaka (Y)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, 1-1-1, Gifu, 501-1196, Japan.

Hisaka Kurita (H)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, 1-1-1, Gifu, 501-1196, Japan.

Isao Hozumi (I)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, 1-1-1, Gifu, 501-1196, Japan. hozumi@gifu-pu.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH